Clinical trials: Severe ARDS
Pulmonary Fibrosis, COVID-19
Pulmonary Fibrosis After Severe COVID-19 Pneumonia
Patients discharged after hospitalization for COVID-19 pneumonia were retrospectively selected by radiologically established criteria that at admission presented at chest computed tomography (CT) (i) normal lung parenchyma <50%…
- Trial name
- SPIFFERO (NCT06423560)
- Testing
- Computed tomography
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- IRCCS San Raffaele
ARDS (Moderate or Severe)
Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS
To verify whether the transpulmonary pressure-guided mechanical ventilation strategy can reduce right ventricular involvement, especially the incidence of acute cor pulmonale (ACP), in patients with moderate to severe ARDS…
- Trial name
- NCT07490925
- Testing
- Transpulmonary pressure guided mechanical ventilation strategy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Beijing Chao Yang Hospital
Acute Respiratory Distress Syndrome (ARDS)
Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)
Randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy of intravenous metoprolol in patients with Acute Respiratory Respiratory Distress Syndrome (ARDS).
- Trial name
- MAIDEN (NCT05847517)
- Testing
- Metoprolol Injection, saline 0.9%
- Where
- 12 sites in Spain
- Volunteers
- 14 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Fluid Responsiveness
Passive Leg Raise and Mini-fluid Challenge Effect on Various Cardiac Output Surrogates for Fluid Responsiveness
In the critically ill population, fluid administration in an unstable patient is perhaps the most common intervention that is performed.
- Trial name
- PHOENIX (NCT06390423)
- Testing
- Passive leg raise, SVI via bioreactance, Echo based VTI
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- CentraCare
Acute Respiratory Distress Syndrom
Selective Lung Recruitment in Moderate to Severe ARDS : a Pilot Study
Acute respiratory distress syndrome (ARDS) is an acute condition affecting the lung after clinical aggression ( infectious process, pancreatitis, acute inflammatory event).
- Trial name
- SRIMSA (NCT06609629)
- Testing
- Selective lung recruitment
- Volunteers
- 10 people
- Sponsor
- University Hospital, Caen
ARDS (Moderate or Severe)
Combining Electrical Impedance Tomography and Thoracic Ultrasound Toinvestigate Dynamic Changes
1. To evaluate the dynamic changes of lung ultrasound during electrical impedance tomography (EIT) PEEP titration and across the first week of ARDS. 2.
- Trial name
- NCT06958770
- Testing
- Electrical impedance tomography
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
Covid19, Covid-19 ARDS
Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
This study was designed to evaluate the efficacy of Remdesivir and Baricitinib combination therapy for the treatment of severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04693026
- Testing
- Remdesivir, Baricitinib, Tocilizumab
- Where
- Bangladesh
- Volunteers
- 150 people
- Sponsor
- M Abdur Rahim Medical College and Hospital
Pneumonia
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult…
- Trial name
- NCT07615010
- Testing
- agenT-797, Standard of Care (SOC)
- Where
- 4 sites in United States, Ukraine
- Volunteers
- 90 people
- Sponsor
- MiNK Therapeutics
SARS-CoV-2 (COVID-19) Severe Pneumonia
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
- Trial name
- NCT04412668
- Testing
- Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- aTyr Pharma, Inc.
Sepsis, Acute Infection
A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.
The study is a multi-center, prospective, observational clinical study enrolling patients from at least 3 medical centers. Study population will include patients over the age of 18 years.
- Trial name
- NCT06665542
- Where
- 8 sites in United States, Israel
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- MeMed Diagnostics Ltd.
Septic Shock, Severe Sepsis
Efficacy of Hydrocortisone in Treatment of Severe Sepsis/Septic Shock Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Severe sepsis/septic shock is a serious condition associated with high mortality rate. Hydrocortisone has been recommended as a useful treatment to decrease mortality in hemodynamically unstable septic shock patients, not…
- Conditions
- Septic Shock, Severe Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Trial name
- NCT01284452
- Testing
- Hydrocortisone
- Where
- Thailand
- Volunteers
- 197 people
- Sponsor
- Mahidol University
Acute Respiratory Distress Syndrome, Chest Trauma
Serum sRAGE, CC16, and Syndecan-1 as Predictors of ARDS and Mortality After Severe Chest Trauma
This prospective cohort study aims to evaluate whether blood levels of soluble receptor for advanced glycation end products (sRAGE), Club Cell Protein-16 (CC16), and Syndecan-1 measured early after severe chest trauma can predict…
- Trial name
- NCT07774338
- Testing
- No intervention - observational study
- Volunteers
- 85 people
- Sponsor
- Assiut University
COVID-19
COVID-19 : Study of INFLAmmasome and PLAtelets Functions
COVID-19 pandemic is a severe viral sepsis characterized by the occurrence of Acute respiratory distress syndrome (ARDS) whose pathophysiology is little described
- Trial name
- CO-QUETTES (NCT04397822)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 61 people
- Sponsor
- University Hospital, Toulouse
Severe Acute Respiratory Syndrome Coronavirus 2
Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
This trial is designed to determine if the inflammation modulating effect of vagus nerve stimulation can improve pulmonary function and limit progression to ARDS in hospitalized COVID-19 hospitalized patients.
- Trial name
- NCT04379037
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation
- Where
- Argentina
- Volunteers
- 50 people
- Sponsor
- Nemechek Technologies
COVID-19 Pneumonia, Thrombosis
Practice Variation on Antithrombotics in COVID-19
Evidence suggests coronavirus disease 2019 (COVID-19) is associated with an increased incidence of thromboembolic manifestations.
- Conditions
- COVID-19 Pneumonia, Thrombosis, COVID-19 Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS) Pneumonia
- Trial name
- NCT04998799
- Testing
- Current clinical practices of participating physicians
- Where
- India
- Volunteers
- 435 people
- Sponsor
- NMC Specialty Hospital
Acute Respiratory Distress Syndrome (ARDS)
Trial of an Alternate Mode of Providing Artificial Breaths to Children With Very Severe Pneumonia
This study attempts to study a new ventilation mode in children with Acute respiratory distress syndrome (ARDS). Despite decades of research, no intervention has brought about a significant decrease in ARDS mortality.
- Trial name
- APRiCE (NCT02167698)
- Testing
- Airway Pressure Release Ventilation (APRV), Low-tidal volume ventilation, Methylprednisolone
- Where
- India
- Volunteers
- 52 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Prone Positioning, High Flow Nasal Cannula
Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and had subsequently spread worldwide. Twenty-nine percent of COVID-19 patients may develop ARDS.
- Conditions
- Prone Positioning, High Flow Nasal Cannula, Acute Respiratory Distress Syndrome, Corona Virus Infection
- Trial name
- NCT04325906
- Testing
- high flow nasal cannula (HFNC), Prone positioning (PP)
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- Rush University Medical Center
COVID-19 Acute Respiratory Distress Syndrome
Efficacy of Respiratory Physiotherapy on Severe ICU-admitted COVID-19 Patients.
COVID-19 is an infectious disease caused by SARS-CoV2 virus. COVID-19 patients can develop a severe disease that can lead to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS).
- Trial name
- NCT05067907
- Testing
- Early physiotherapy
- Where
- 4 sites in Italy
- Volunteers
- 244 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Respiratory Distress Syndrome, Acute, Severe Community-Acquired Pneumonia
Multimodal Database and Large Language Model for ARDS
The goal of this observational study is to integrate existing clinical cohorts from the research team to establish dedicated cohorts for ARDS and high-risk ARDS patients (primarily SCAP patients), then systematically collect…
- Trial name
- NCT06973733
- Testing
- Clinical data and biospecimen collection
- Volunteers
- 6,500 people
- Sponsor
- China-Japan Friendship Hospital